Elif Ersoy Callioglu
Elif Ersoy Çallıoğlu is an Otolaryngology–Head and Neck Surgery specialist at Ankara Bilkent City Hospital. She has graduated from Ege University Faculty of Medicine in 2000 and completed his residency training in Otolaryngology–Head and Neck Surgery at the same university in 2005. She served as an observer at the pittshburg university , focusing on head and neck surgery and robotic surgery. She was awarded the title of Associate Professor in 2020.
Dr. Ersoy Çallıoğlu has contributed chapters to both international and national books. She has presented her research at national and international conferences and has received awards at both levels. She has authored and co-authored great number of publications. She has served in various roles for numerous journals, including as an advisory board member and reviewer. She is a member of several national and international societies. Her main interests include head and neck surgery, transoral laser surgery (including laryngectomy procedures), transoral robotic surgery, and thyroid surgery
Sessions
Description
This session reviews the critical molecular landscape of head and neck squamous cell carcinoma (HNSCC). We will examine key genetic alterations and signaling pathways, including TP53, NOTCH1, and EGFR/PI3K. The presentation highlights how these genetic drivers influence tumor progression, metastasis, and resistance to current treatment modalities, offering a snapshot of the current genomic understanding of the disease.
Outcome Objectives
Identify major genetic mutations and chromosomal alterations associated with head and neck cancer.
Understand the relationship between specific genetic pathways and clinical disease behavior.
Evaluate the potential of these genetic pathways as targets for future precision medicine and therapeutic interventions.
Background
Head and neck cancer exhibits significant molecular heterogeneity, which often complicates treatment and prognosis. While traditional risk factors are well-known, the underlying genetic mechanisms driving carcinogenesis are complex. Elucidating these genetic pathways is essential for developing novel biomarkers and targeted therapies, ultimately aiming to improve survival rates and reduce treatment-related morbidity.